Design, fabrication and characterisation of Si-based capillary-driven microfluidic devices

Micro & nano letters

article

Yifei Ye¹  Yang Zhao¹  Jie Cheng¹  Mingxiao Li¹  Chengjun Huang¹ 

[1] R&D Center of Healthcare Electronics, Institute of Microelectronics, Chinese Academy of Sciences;School of Future Technology, University of Chinese Academy of Sciences

关键词: self-assembly;    capillarity;    etching;    silicon;    catalysis;    microfluidics;    monolayers;    elemental semiconductors;    copper;    microfabrication;    contact angle;    hydrophilicity;    photolithography;    buffer loading;    flow resistor;    micropillar array;    surface modified device;    controllable autonomous capillary flow delivery;    sequential capillary flow generation;    controlled flow rate;    propagation distance;    effective capillary pump;    point-of-care testing systems;    lidless silicon-based capillary-driven microfluidic device;    deep silicon etch technique;    surface hydrophilisation modification method;    copper-catalysed azide-alkyne cycloaddition reaction;    snake-shaped microchannel;    self-pumping;    self-assembly monolayer;    lithographic technique;    contact angle;    aspect ratio;    size 25.0 mum;    size 5.0 mum;    size 120.0 mm;    size 0.05 mm;    depth 0.025 mm;    Si;    Cu;   

DOI  :  10.1049/mnl.2018.5120

学科分类：计算机科学（综合）

来源: Wiley

【 摘 要 】

Osteoarthritis is the most prevalent arthritic disease and a leading cause of disability. The pathogenesis of osteoarthritis involves multiple etiologies, including variable degree of synovial inflammation. Metformin and pioglitazone could potentially reduce the levels and activity of inflammatory mediators. This may consider as a new therapeutic approach added to the current used drugs in an attempt to decrease the pain, inflammation, and improve daily activity and quality of life in patients with knee osteoarthritis. This study designed to evaluate the clinical utility of using metformin or pioglitazone as anti-inflammatory agents in combination with non-steroidal anti-inflammatory drugs (NSAID) of selective type of cyclooxygenase-2 (COX-2) inhibitor, meloxicam, in the treatment of knee osteoarthritis (OA). Randomized, double blinded clinical study was performed on 98 patients who have symptomatic and radiologic evidence of painful OA of the knee (57 patients only completed the study). Patients were allocated into three groups, group (A); 20 patients treated with meloxicam (15mg/day) alone, group (B); 20 patients treated with metformin (1000mg/day) + meloxicam (15mg/day) and group (C); 17 patients treated with pioglitazone (15mg/day) + meloxicam (15mg/day). The treatment was followed for 12 weeks through measurement of the clinical effects of drugs each 7 days, using the Knee Injury and Osteoarthritis Outcome Score (KOOS) system. The results showed that metformin or pioglitazone, when used in combination with NSAID resulted in significant improvement in the components of KOOS, higher than that produced by meloxicam when used alone. In conclusion, administration of metformin or pioglitazone as adjuvant therapy to NSAID, meloxicam, in OA patients produced very well characterized analgesic and anti-inflammatory activities, and improves the therapeutic profile of meloxicam.

【 授权许可】

CC BY|CC BY-ND|CC BY-NC|CC BY-NC-ND